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(57) ABSTRACT 
A method and apparatus for dynamically controlling the 
crystallization of molecules including a crystallization 
chamber (14) or chambers for holding molecules in a 
precipitant solution, one or more precipitant solution reser- 
voirs (16, IS), communication passages (17, 19) respec- 
tively coupling the crystallization chamber(s) with each of 
the precipitant solution reservoirs, and transfer mechanisms 
(20, 21, 22, 24, 26, 28) configured to respectively transfer 
precipitant solution between each of the precipitant solution 
reservoirs and the crystallization chamber(s). The transfer 
mechanisms are interlocked to maintain a constant volume 
of precipitant solution in the crystallization chamber(s). 
Precipitant solutions of different concentrations are trans- 
ferred into and out of the crystallization chamber(s) to adjust 
the concentration of precipitant in the crystallization 
chamber(s) to achieve precise control of the crystallization 
process. The method and apparatus can be used effectively 
to grow crystals under reduced gravity conditions such as 
microgravity conditions of space, and under conditions of 
reduced or enhanced effective gravity as induced by a 
powerful magnetic field. 
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DYNAMICALLY CONTROLLED 
CRYSTALLIZATION METHOD AND 
APPARATUS AND CRYSTALS OBTAINED 
THEREBY 
spent crystallizing proteins for analysis of their structures. 
Recent biotechnological developments in cloning and over- 
expression of genes encoding proteins of interest and in the 
purification of proteins are increasing the need for a reliable 
s way in which to grow protein crystals. Unfortunately protein 
crystallization is a difficult and unpredictable art. 
Crystallization of a biological molecule such as a protein 
involves the creation of a supersaturated solution of the 
molecule under conditions that promote minimum solubility 
10 and the orderly transition of the molecules from the solution 
into a crystal lattice. The variables that must be controlled 
This application is a continuation of application Ser. No. 
091025,475, filed Feb. 18, 1998, now U.S. Pat. No. 5,961, 
934. 
GOVERNMENT LICENSE RIGHTS 
The U.S. Government has a paid-up license in this inven- 
tion and the right in limited circumstances to require the 
patent Owner to license others on reasonable terms as 
provided for by the terms of Contract No. NAS8-97010 
Precisely to Promote crystal growth include temperature, 
protein solution concentration, salt solution concentration, 
pH, and gravitational field, for example (Dubin, s. &k Feher, 
15 G. Ann Rev Phvs Chem 47 (1996) 171-204. the entire ;warded by NASA, George C. Marshall Space Flight 
Center, and Grant No. 2R44GM53300-02 awarded by NIH 
and the National Institute of General Medical Sciences. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the formation of crystals 
of small and large molecules, including macromolecules 
such as proteins and nucleic acids, and more particularly, to 
a method and apparatus for dynamically controlling the 
process of forming such crystals, and the resulting crystals. 
2. Description of the Related Art 
There is great interest in determining the three- 
dimensional (3-D) structures of biological molecules. Ongo- 
ing studies of the genomes of humans and other mammals, 
as well as of disease-causing viruses, bacteria, and parasites, 
are identifying thousands of genes and proteins, many of 
which are linked to diseases of humans and domestic 
animals and plants. Knowing the 3-D structures of the 
molecules that are involved in causing a disease can be a 
tremendous aid in developing drugs to prevent or treat the 
disease. Rational drug design involves obtaining a precise 
3-D structure of a specific molecule involved in a disease 
process, making and studying physical models and 
computer-generated graphic images of the structure, as well 
as using sophisticated computer programs that thermody- 
namically model the structure and its interactions with 
solvent and other molecules, in order to design drugs that 
selectively bind to and alter the function of the disease- 
causing molecule. Rational drug design can be used to 
analyze and design drugs that interact with small molecules 
such as peptide and non-peptide hormones, as well as 
intermediate-sized and large macromolecules such as 
nucleic acids and proteins, respectively. The application of 
rational drug design will result in a number of diseases and 
pathological symptoms being brought under control. For 
example, CAPTOPRIL is a well known drug for controlling 
hypertension that was developed through rational drug 
design techniques. CAPTOPRIL inhibits generation of the 
angiotension-converting enzyme thereby preventing the 
constriction of blood vessels. 
X-ray crystallography is a technology that allows us to 
obtain the precise 3-D atomic structures of molecules such 
as peptides, proteins, and nucleic acids. A critical step in 
using X-ray crystallography to determine the 3-D structure 
of any molecule of interest is establishing a reliable method 
for crystallizing the molecule. Proteins are one of the major 
classes of structural molecules in living organisms; protein 
enzymes catalyze the metabolic reactions that make life 
possible; and many disease processes are mediated by the 
interactions of proteins with other molecules, including 
other proteins. Therefore, much time and money have been 
\ ,  
contents of which are incorporated herein by reference). 
These variables are carefully controlled and optimum com- 
binations thereof are determined through experimentation to 
yield superior crystals. 
In the description of the invention that follows, the 
molecule being crystallized, e.g., the protein, is referred to 
as a “reactant,” and the solution containing one or more 
precipitants that is used in crystallization processes is 
referred to as a “reagent” solution. 
The crystallization process generally involves three dis- 
tinct phases; nucleation, sustained crystal growth, and ter- 
mination of crystal growth. Nucleation is the initial forma- 
tion of an ordered grouping of a few reactant molecules and 
3o requires a particular concentration of reactant molecules in 
a precipitating reagent solution. On the other hand, the 
continued growth phase consists of the addition of reactant 
molecules to the growing faces of the crystal lattice and 
requires lower concentrations of reagent solution than the 
35 nucleation phase. The termination phase can be initiated by 
poisoning the growing lattice with denatured or chemically 
modified reactant molecules or with different molecules, by 
depletion of the reactant solution, or by changing the con- 
centration of precipitant to a specified level. 
It is considered desirable to obtain a small number of 
crystallization nuclei quickly that will grow slowly into 
full-sized crystals. Theoretically, this allows for a relatively 
large size of the resulting crystals, homogenous crystal order 
and morphology, and balanced crystal dimensions. 
45 Therefore, it is desirable to begin crystallization with a 
reagent solution containing a particular concentration of 
precipitant until nucleation is detected, at which point it is 
desirable to adjust the concentration of precipitant. Thus, 
one of the critical requirements of any molecular crystalli- 
zation process is the fine and dynamic control of the various 
parameters that determine the concentration of the precipi- 
tant in the solution in which the target reactant molecule 
protein is suspended. This control requires the ability to 
attain nucleation conditions and the ability to modify the 
55 concentration of the precipitant without disturbing the crys- 
tallization process. 
There are several conventional techniques for forming 
molecular crystals; for example, liquid diffusion, vapor 
diffusion and dialysis techniques. These processes are rela- 
60 tively slow and cannot be readily controlled dynamically. 
Therefore, these processes require complex and large appa- 
ratus in order to control crystallization, if crystallization can 
be controlled at all. Accordingly, it is desirable to overcome 
these limitations. 
Most conventional protein crystallization methods mix a 
solution containing the reactant protein molecules with a 
crystallizing, or precipitating, solution to accomplish crys- 
2o 
25 
4o 
65 
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tallization. In terms of mechanics, use is commonly made of not facilitate experimentation in which the only variable is 
syringes, stepping motors, valves of various types, mem- the presence or absence of the earth’s gravitational field 
branes to separate solutions, and in one case, a gel to replace because conventional crystallization apparatus must be 
the membrane and act as a delaying filter device between modified significantly for use in space, Given the 
solutions. U.S. Pat. NOS. 4,917,707, 5,106,592, and 5,641, s unpredictable, multifactorial nature of the crystallization 
681, and Microdialysis CrYstallization Chamber, L. c .  process, and its dependence on the structure of the molecule 
Sicker, J. Crystal Growth 90 (1988) 349-3573 the entire which is being crystallized, it is also envisioned that Some 
contents Of which are incorporated herein by reference, molecules will crystallize efficiently in gravitational fields 
that are greater than earth’s gravitational field. The forego- disclose these concepts. 
It is known to ‘‘control” the crystallization Process. 10 ing methods and apparatus do not provide a dynamic control 
capability, either in the earth’s gravitational field or in However, Only the movement Of liquids via pumps, 
and syringes is controlled in conventional crystallization 
processes. This control creates a static condition (bath 
concentration) which is predefined for the protein in ques- 
tion. For example, U.S. Pat. No. 4,755,363, the entire 
contents of which are incorporated herein by reference, 
discloses delivering liquids at desired flow rates and con- 
centrations. However, U.S. Pat. No. 4,755,363 fails to dis- 
close changing conditions within the crystallization chamber 
(with the exception of temperature) once those conditions 
have been set and crystallization has begun. 
Temperature is an important parameter that can be ‘On- 
trolled to optimize conditions separately for nucleation or 
gravitational fields that are greater or lesser than earth’s 
gravitational field, 
The advantages obtained by growing crystals in reduced 
15 gravity in space can also be obtained on the earth’s surface 
by growing crystals under conditions in which the effective 
gravitational field <gef) is reduced as a result of diamagnetic 
effects induced by a very high magnetic field. Provided that 
a magnet of sufficient strength is used, a solution containing 
20 reactant molecules can be moved to positions with respect to 
the center of the magnet so that the reactant molecules 
experience g, forces that range between zero and twenty 
times normal earth gravity (E, Beaugnon et al,, Nature 
growth. u.s. Pat. Nos. 4,755,363 and 5,362,325, the entire (1991) 3491470). A study of lysozyme crystallization under 
contents Of which are incorporated herein by reference, are 25 conditions where gef was varied magnetically from 0.95 to 
in crys- 1.05 g suggested that crystal growth is enhanced in a strong 
magnetic field, possibly because alignment of the reactant 
Of patents 
processes. u.s. Pat. No. 5,362,325 
temperature 
varying the concentration of a crystallizing agent over time molecules in the magnetic field leads to formation of 
to produce a predetermined gradient in the concentration Of 
the crystallizing agent. However, this reference 
ordered crystals (N, 1, Wakayama et al,, J, Crystal Growth 
to 30 (1997) 1781653; see also, G, Sazaki et al,, J, Crystal Growth 
methods or apparatus that provide a dynamic control caps- 
bility for crystallization under magnetically-induced effec- 
tive gravitational fields where gef is greater or lesser than 
disclose dynamic control as disclosed for this invention. (1997) 1731231), None of the foregoing references discloses 
Automation is a recent trend in crystallography. Robotics 
enables systematic pipetting of solutions and protein into 
crystal growth chambers on Plates, so that a multiplicity of 
conditions can be examined more quickly and consistently. 35 normal earth gravity, 
The use of robotics frees valuable time for researchers. 
Another trend is the use of semi-automated techniques to 
record results. 
SUMMARY OF THE INVENTION 
Also, inherent to any crysta~~ization process that proceeds The present invention is a Crys- 
convection, thermal effects, sedimentation, and buoyancy, methods that can be to a crysta11i- 
in a finite gravitational field are the effects of molecular 40 System (DCCS) that apparatus and 
Crystallization experiments that have been conducted in 
microgravity (1/1000 to 1/10,000 g) on board the space 
Shuttle, space Station, and other vehicles, indicate that 
larger and more homogenous crystals can be grown in 45 time. 
microgravity environments by eliminating the effects of the 
earth’s gravitational field. Several patents disclose crystal- 
lization in microgravity to improve the size, morphology 
and diffraction quality of crystals. U.S. Pat. Nos. 5,362,325 
and 4,755,363, which are incorporated herein by reference, SO reversal of a molecular crysta~~ization process, 
are exemplary of patents disclosing microgravity crystalli- 
zation. In fact, a low gravity environment is “crucial” 
(emphasis added) to the success of one apparatus (Sygusch, 
et al. J. Crystal Growth 162 (1996) 167-172). However, the 
practical limitations of using current space vehicles, such as ss 
the Space Shuttle, render it difficult to use conventional 
‘ation process precisely and 
The present invention can be further used to monitor and 
control a molecular crystallization process remotely in real 
The present invention can be further used to control a 
molecular crystallization process in a predetermined man- 
ner. 
The present invention permits initiation, termination or 
The present invention permits reduction in the size and 
number of moving parts in a molecular crystallization 
method and apparatus, 
The present invention permits production of molecular 
in a system’ 
apparatus/methods for crystallization in microgravity envi- The Present invention can be used to Produce molecular 
ronments. Particularly, conventional apparatus are too large, crystals under conditions of real and simulated gravity in the 
many moving parts that can fail, do not permit accurate 60 to about 20 times the earth’s gravitational field, and to 
are difficult to control remotely and automatica~~y, have 
change of solution concentration during the process and are 
not entirely reusable. Also, known processes require too 
much time to produce fully grown crystals, Therefore, it is 
desirable to overcome these deficiencies to permit crystal 
growth experiments in space under conditions in which 65 Pressure in the CrYstalliZation chamber. 
gravity ranges below earth gravity down to microgravity 
conditions. Also, conventional apparatus and methods do 
range of from about zero times the earth’s gravitational field 
produce crystals in earth’s gravitational field, with identical 
apparatus. 
The present invention permits crystallization parameters 
to be controlled in a sealed system without changing the 
The present invention can be used to optimize the time 
required to produce large, well-ordered molecular crystals, 
US 6,596,081 B1 
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The present invention can be used to optimize crystalli- The invention can also be configured so that two or more 
zation conditions while using less experiments and substan- crystallization chambers are coupled via a manifold solution 
tially less reactant, e.g. protein. communication means to at least one source reagent solution 
‘‘Dynamic control’’ as used herein means that: (1) the reservoir, and are also coupled via solution communication 
crystallization process can be started at will, (2) several 5 means, directly or indirectly, to one or more drain reservoirs, 
conditions that are important for the growth of molecular SO that the same volume of reagent solution can be trans- 
crystals, such as pH, conductivity, and temperature, can be ferred simultaneously from the source reservoir to each of 
measured in the crystallization chamber, (3) decisions the two or more different crystallization chambers. 
regarding altering the conditions affecting crystal growth By configuring crystallization chambers according to the 
can be made based upon monitoring crystal nucleation and invention so that the reactants in different crystallization 
growth, (4) these conditions can be precisely controlled at chambers experience a range of different precipitant con- 
any time during the crystallization process, (5) the crystal- centrations and other parameters that affect crystallization; 
lization process can be modified or stopped when desired e.g., in multiple series, or in 2- and 3-dimensional arrays, the 
and (6) the process can be reversed if so desired. invention permits controlled variation of the concentrations 
In order to achieve these objectives, a first aspect of the of one or more precipitants during the process, resulting in 
invention includes at least one crystallization chamber for establishing conditions for crystal growth, optimization, 
holding a solution containing reactant molecules that is termination or reversal of the crystallization process, and 
separated by a Permeable membrane from a reagent solution conservation of the molecular crystal. The invention thus 
comprising a Precipitant at a first concentration, at least one permits the crystallization process to be controlled easily, 
source reservoir comprising reagent solution having precipi- merely by operating the transfer mechanisms, 
Another important feature of the present invention is that tant at a second concentration that is coupled via a commu- 20 nication passage with the reagent solution in the crystalli- it has real time remote-controlled operative capabilities, and zation chamber, and at least one drain reservoir that is 
reagent solution in the crystallization chamber, and transfer conditions, as well as in environments in which the real or 
mechanisms configured to respectively transfer reagent 2s simulated gravitational field is greater or less than earth’s 
solution between the at least one source reagent solution gravitational 
reservoir and the crystallization chamber, and to concur- The invention also permits a complex set of variables in 
rently transfer reagent solution from the crystallization the process of crystal growth to be rigorously examined, 
chamber to the at least one drain reservoir. The transfer manipulated and controlled so that gravity is the only 
mechanisms can work in tandem to simultaneously transfer 30 variable. Due to its compactness and ease of operation, the 
equal amounts of precipitating solution into and out of the present invention is conservative in terms of cost contain- 
crystallization chamber, to thereby alter the concentration of ment for flights aboard the Space Shuttle and the Interna- 
precipitant in the reagent solution in the crystallization tional Space Station. Use of this invention conserves both 
chamber with respect to time. In this manner, the concen- money and valuable astronaut time. The present invention 
tration of the precipitant in the reagent solution in the 35 can remain on a space platform for many sets of 
crystallization chamber can be adjusted dynamically to experiments, while the crystallization chamber can return to 
provide optimum crystallization conditions with respect to earth with the molecular crystals that are produced in space. 
time. New chambers, tubing and syringes can be delivered on the 
The invention can also be configured SO that two or more next flight pre-loaded. Furthermore, the invention can be 
pairs of sourceidrain reservoirs, each containing a different 4o readily miniaturized SO that it is even more compact than the 
reagent solution, are respectively coupled via separate solu- ~ ~ b o d i m e n t s  shown in the examples disclosed herein, and 
tion communication means to the reagent solution in the thus the entire unit can be made even less expensive to 
crystallization chamber, with separate solution transfer transport to and from space. 
means to transfer reagent solutions tandemly from the The present invention further provides methods for car- 
source reservoir to the crystallization chamber, and from the 45 rying out dynamically controlled crystallization of proteins 
crystallization chamber to the respective drain reservoir, for and other molecules under conditions in which the effective 
each pair of reagent reservoirs. The paired source and drain gravitational force resulting from diamagnetism in a high 
reservoirs can be operated sequentially, i.e., one pair at a magnetic field (i.e., 16 Tesla or more) is in the range of zero 
time, with time allowed for diffusion-mediated mixing of the to 20 times earth’s gravitational field. 
reagent solution in the crystallization chamber between so Another important feature of the invention is that the 
transfers, so that precipitant concentration in the reagent and apparatus is compact and easily sealed to the air. Sealing the 
reactant solutions in the crystallization chamber is changed system permits operation without adverse effects on fluid 
in an even, controlled manner. flow and the sieving properties of the dialysis membrane in 
The invention also can be configured with two or more the crystallization chamber being caused by changes in air 
crystallization chambers coupled in series via solution com- ss pressure. Sealing also prevents contamination of the solu- 
munication means, with at least one source reagent solution tions in the system sample for further experimentation. 
reservoir being coupled to the reagent solution of the first An additional feature of the invention is that it produces 
crystallization chamber in the series, and at least one drain crystals in a reduced time with few moving parts and low 
reservoir being couuled to the reagent solution of the last uower reauirements. 
1s 
coupled via a separate communication passage with the can be under earth gravitational 
I _  I 
BRIEF DESCRIPTION OF THE DRAWINGS crystallization chamber in the series. Tandem transfer of a 60 volume of reanent solution from a source reservoir to the 
first crystallizazon chamber, and from the last crystallization 
chamber to a drain reservoir, results in transfer of an equal 
volume of reagent solution from each crystallization cham- 
ber in the series to the next one, thereby establishing a 6s controlling the CrYstallization apparatus. 
concentration gradient of a precipitant in the reagent solu- 
tion across the series of crystallization chambers. 
FIG. 1 is a detailed SChematic view of a CrYstalliZation 
FIG. 2 is a schematic illustration of a controller for 
FIG. 3 is a detailed schematic view of an embodiment of 
a crystallization chamber in which a dialysis membrane 
apparatus of the invention. 
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separates reactant solution in a chamber in the top assembly 
from reagent solution in the lower portion. 
FIG. 4 is a detailed top view of an embodiment of a 
crystallization chamber, showing attached ionic strength, 
pH, and temperature probes. 5 that is being crystallized. 
FIG. 5 schematically depicts a series of crystallization 
chambers that are connected to each other by small diameter 
tubing, with the first and last crystallization chambers being 
connected via tubing to source and drain reservoirs (e.g., 
syringes), respectively. 
FIG. 6 schematically depicts a row of crystallization 
chambers connected via manifolds to source and drain 
reservoirs. Chem. (1996) 47:173). 
tion chambers, with the crystallization chambers of the rows 
being connected via manifolds to one pair of source and 
drain reservoirs, and the crystallization chambers of the 
columns being connected via manifolds to a different pair of 
source and drain reservoirs. 
FIG. 8 schematically depicts a series of crystallization 
chambers in the bore of a magnet capable of generating 
gravity at earth’s surface. 
success to crystallize molecules other than proteins, such as 
small organic molecules and medium-sized molecules such 
as oligon~cleotides and OkoPePtides. 
The term “reactant” as used herein refers to the molecule 
The terms “precipitant” and “reagent” as used herein refer 
to chemical compounds which affect the solubility of the 
molecules being crystallized and which, depending on their 
concentration, can promote or inhibit crystal growth in 
lo crystallization processes. Examples of chemical compounds 
that are Precipitants are salts, Polyethylene glycol, and small 
organic molecules (Durbin, S. 8~ Feher, G., Ann. Rev. Phys. 
The term “reagent solution” as used herein refers to a 
solution comprising one Or more Precipitants. 
FIG. 1 illustrates protein crystallization apparatus 10 in 
accordance with the invention. Apparatus 10 includes rigid 
base plate 12, crystallization chamber 14 in which crystal- 
2o lization is to occur, syringe 16, syringe 18, lead screw 22, 
Yoke 24, and guide rods 26 and 28. Solution containing the 
reactant molecules to be crystallized is removably disposed 
crystallization chamber 14 by tube 17 serving as a conduit. 
25 Syringe 18 is coupled to crystallization chamber 14 by tube 
DETAILED DESCRIPTION OF THE 19 serving as a conduit. Syringes 16 and 18 serve as reagent 
INVENTION solution reservoirs as described in detail below. Plungers of 
While specific embodiments and preferred methods and syringe 16 and syringe 18 face in opposing directions and 
materials of the invention are described herein, the invention are coup1ed to yoke 24 which as 
is not limited to the particular methodo~ogy, protoco~s, and 3o described below. Further, yoke 24 is disposed so that it slides 
materials described. It is understood that methods, materials, On guide rods 26 and 28. Lead Screw 22 is coup1ed to a shaft 
FIG, 7 schematically depicts a 2-D matrix of crystalliza- 15 
effective gravitational fields of from between 0 to 2 times the inside crystallization chamber 14. Syringe 16 is coupled to 
as an 
and devices similar or equivalent to those described herein 
can be used successfully in the practice or testing of the 
Of motor 2o via 
yoke 24 via a threaded 
21 and is engaged with 
Syringe 16, syringe 18, 
present invention, and that the present invention as 
described herein is capable of further modifications. This 35 plate l2 by mounting 
adaptations of the invention following, in general, the prin- 
guide rod 26 and guide rod 28 are fixedly coupled to base 
31 as shown. 
has a bearing for permitting rotation of lead screw 22 while 
30 and 
application is intended to cover any variations, uses, or 
ciples of the invention and including such departures from 
the present disclosure as come within known or customary 
practice within the art to which the invention pertains and as 40 fixed to base plate l2 by 
32 is fixed to base plate l2 by 31 and 
fixing lead Screw 22 to base Plate 12. Further, 
to 
crysta11ization chamber l4 and stepper motor 2o are 
31. Spring 29 is 
may be applied to the essential features set forth herein and base plate l2 by Screw 31 at One end and to yoke 24 at 
as f o ~ ~ o w s  in the scope of the appended claims, ~ 1 1  another end to bias yoke 24 in one direction against threads 
publications, patents, and patent applications mentioned of lead Screw 22 to thereby minimize backlash when yoke 24 
herein are incorporated by reference for the purpose of is moved linearly as described below. The invention operates 
describing and disclosing the materials and methodologies 45 successfully without spring 29, and its use is optional. 
which are reported in the publications, patents, and patent The reactant molecules that can be crystallized by the 
applications, which might be used in connection with the present invention include, but are not limited to, macromol- 
invention. Unless defined otherwise, all technical and sei- ecules such as proteins, nucleic acids in combination with 
entific terms used herein have the Same meaning as corn- proteins, proteins bound to lipids and glycolipids. If the 
monly understood by one of ordinary skill in the art to which so reactant molecules are membrane-bound proteins, a deter- 
this invention belongs, It must also be noted that as used gent can be introduced into the crystallization chamber at an 
herein and in the appended claims, the singular forms “a”, appropriate time, by a micro-syringe, or the like, to separate 
“and,” and “the” include plural reference unless the context the protein from the membrane. The reactant molecules can 
clearly indicates otherwise. For example, reference to “a also be small molecules such as drug molecules, co-factors, 
molecule to be crystallize#’ includes a plurality of such 5s amino acids, nucleotides, hormones and other signaling and 
molecules. The present invention comprises an apparatus regulatory molecules, and a d o g s  of the foregoing. 
and method for producing molecular crystals that permit the Medium-sized molecules that can be crystallized by using 
monitoring of crystal growth and dynamic control of the the Present invention include, but are not limited to, 
crystallization conditions so that large, high quality crystals peptides, protein fragments, and oligonucleotides. Large 
are produced in a relatively short times. The methods and 60 macromolec~lar complexes such as viruses can also be 
apparatus of the present invention can be used to crystallize crystallized using the present invention. 
molecules ranging in size from small organic compounds of Crystallization chamber 14 comprises a system for retain- 
about l e 3 0  atoms up to large macromolecular complexes ing the reactant molecules, but allowing for the passage of 
comprising tens of thousands of atoms. The description that smaller molecules. A permeable membrane, porous 
follows often refers to using the method and apparatus of the 65 diaphragm, or permanent sieve, having a molecular weight 
present invention to crystallize a protein; however the meth- cut-off of a predetermined value may be used in this regard. 
ods and apparatus described herein can be used with equal For example, the membrane may be a dialysis bag or a sheet 
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of dialysis membrane. In any case, the molecular weight A reagent solution is loaded into syringe 16, and option- 
cut-off should be lower than the molecular weight of the ally into syringe 18 also. Each of the reagent solutions that 
reactant molecules in the crystallization chamber, and are used in the crystallization chamber and syringes can 
should significantly reduce movement of the reactant mol- contain one Or more of any Precipitants having ionic Or 
ecules out of the crystallization chamber. However, the s chemical characterist ics that, at the appropriate 
membrane or sieve should not significantly hinder the move- concentration, permit crystallization of the protein. The 
merit of smaller precipitant mo~ecu~es, e g,, ions and non- relative concentrations of reagent solution in the crystalli- 
ionic solutes, one embodiment, a solution containing zation chamber(s) and in the solution chambers can be 
crystallization chamber for retention of the macromolecules, i o  and method Of the present invention are wed to raise Or 
and reagent solution is disposed around the dialysis sack 15 lower the concentration of reagent solution in the crystalli- 
to comp~ete~y fill the crysta~~ization chamber, as shown zation chamber(s) to a desired value for crystallization. 
schematically in FIG. 1. In a preferred embodiment, the The conduits that carry reagent solution between the 
crysta~~ization chamber comprises a sieving membrane such paired reagent solution reservoirs and the crystallization 
as a dialysis membrane that separates the crysta~~ization chamber are connected to the portion of the crystallization 
chamber into two compartments, one of which contains chamber containing reagent solution at any points that are 
reactant solution, and the other of which contains a reagent sufficiently far apart that the reagent solution introduced into 
solution, F~~ the crystallization chamber from the source reservoir is well 
prise a top mixed with the reagent solution in the crystallization cham- 
itself may be recessed for this purpose, or the may 2o ber before being drawn out of the crystallization chamber 
comprise a button-shaped protrusion that is recessed for this and into the conduit leading to the drain reservoir. For 
purpose. Preferably the cover comprises a recess that serves example, FIG. 1 shows tubing 17 and 19 from syringes 16 
as a compartment into which is put solution containing and 18, respectively, making connection to the same side of 
reactant molecules for crystallization. The recess is than CrYstalliZation Chamber 14, and FIG. 3 shows the tubing 
covered by a membrane as described above, elastic 25 from the source and drain reagent solution reservoirs making 
~ - ~ i ~ ~ ,  gasket or other retainer may be used to hold the connection to opposite sides of the crystallization chamber. 
membrane in place, A preferred embodiment of the crystal- 
lization chamber is shown in FIG. 3. Transparent top cover the threaded insert of the inlet tube 48 is shown. 
49 comprising a cylindrical protrusion is fitted onto inside 
cover 41 with the center protrusion of cover 49 fitting into 30 and thereby will cause yoke 24 to slide linearly along guide 
the central hole and partially through the hollow cylindrical rods 26 and 28. Linear motion of yoke 24 will cause the 
protrusion of cover 41 to form recession 42, and is secured plunger of syringe 16 to move in one direction and will 
in place with three screws. Recession. 42 is filled with cause the plunger of syringe 18 to move in the opposite 
reactant solution containing the molecule to be crystallized, direction through the same distance. The simultaneous, 
and the opening is covered with dialysis membrane 43 that 3s opposing motions of the plungers in the two syringes cause 
is held in place with an O-ring 44. Alternatively, the opening one syringe to inject a drop of reagent solution into the 
reactant macromolecules to be crystallized is loaded into the varied, based on crystallization conditions. The apparatus 
the crysta~~ization chamber can 
that includes a recessed portion; the 
For additional clarity, FIG. 3 has a cutaway view in which 
Activation of motor 20 will cause lead screw 22 to rotate 
at the bottom of the perforated, cylindrical protrusion of reagent reservoir of the crystallization chamber while the 
inside cover 41 is obturated with a dialysis membrane 43 other syringe withdraws an equal volume of solution from 
that is held in place with an O-ring 44, and reservoir 45 in the same reservoir. For example, activation of motor 20 in a 
with the desired reagent. The inside cover is then placed on X shown in FIG. 1 will cause reagent solution stored in 
the lower portion 46 so that the exposed surface of the syringe 16 to be transferred into crystallization chamber 14 
dialysis membrane is fully in contact with the reagent while simultaneously causing reagent solution to be trans- 
solution and there are no air bubbles in the crystallization ferred out of crystallization chamber 14 and into syringe 18. 
chamber, and the inside cover is secured in place with three 45 If the concentration of precipitant in the reagent solution 
screws. Reactant solution, e.g. a solution containing a pro- resulting in crystal formation is known, the respective con- 
tein to be crystallized, is added through the hole in the top centrations of precipitant in the reagent solutions in crystal- 
of the inside cover to the recess having as its base the upper lization chamber 14, syringe 16, and syringe 18, can be set 
surface of the dialysis membrane. Transparent top cover 49 to the appropriate different values prior to crystallization, 
is then placed on the inside cover with the center protrusion 50 and the concentration of precipitant in the reagent solution 
fitting into the central hole of the inside cover, and is secured in crystallization chamber 14 can be controlled with respect 
the lower, portion of the crystallization chamber 46 is filled 40 direction causing yoke 24 to move in the direction of arrow 
in place with three screws. Cover seals 47 prevent solution 
from leaking out of the chamber. The volume of recession 42 
to time by operating motor 20 in a desired manner over time. 
The optimal time period for dynamically adjusting the 
that is formed when the two covers are assembled is deter- precipitant concentration in the crystallization chamber to a 
mined by the diameter of the hole through the inner cover, 5s concentration giving crystals of the desired size can then be 
and the difference in the length of the hollow cylindrical determined empirically. 
protrusion extending from the inner cover and by the length For example, for certain proteins, it has been found that a 
of the solid cylindrical protrusion extending from the top salt concentration of about 0.15 M (molesfliter) in the 
cover. The volume of recession 42 can range from about 10 reagent solution facilitates crystallization. Also, it has been 
microliters to 500 microliters or more. The volume of the 60 found that it is desirable to approach this concentration very 
reagent solution reservoir 45 in the lower chamber can range slowly and that the rate of approach can be critical in 
from about 50 microliters to 10 ml or more. In a preferred yielding desired results. Therefore, in the preferred 
embodiment, the volume of recession 42 is about 50 embodiment, crystallization chamber 14 and syringe 18 can 
microliters, and the volume of reagent solution reservoir 45 initially contain reagent solutions comprising precipitant at 
is one ml. The invention also includes other ways to retain 65 a concentration that is sufficiently high that crystallization 
the reactant molecules in the crystallization chamber that does not occur (1 M salt, for example), and syringe 16 can 
will be readily apparent to those skilled in the art. initially contain a reagent solution comprising precipitant at 
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a concentration that is lower than the concentration that 52 and external components such as motor 20, programming 
permits crystallization (0.1 M salt, for example). With this terminal 70, display 80 and any sensors or actuators. 
arrangement to initiate a crystallization process, motor 20 Input connector 60 includes three input connections for 
can be activated to move yoke 24 in the direction of arrow motor voltage (+M) a 5 volt D.C. logic voltage (+5), and a 
X in FIG. 1, to thereby transfer a small amount of low 5 ground (G). Input connections of connector 60 are coupled 
concentration reagent solution from syringe 16 into crystal- to I/O circuit 56. Output connector 90 includes output 
lization chamber 14 and simultaneously transfer high con- connections for a first winding of motor 20 (Ml), a second 
centration reagent solution from crystallization chamber 14 winding of motor 20 (M2) and ground (G). Output connec- 
into syringe 18. It can be seen that this procedure lowers the tions of connector 90 are coupled to I/O circuit 56 and to 
concentration of the precipitant in crystallization chamber stepper motor 20 at (a) (as indicated in FIGS. 1 and 2.) 
14. Motor 20 can be activated in desired increments in a Programming terminal 70 is coupled to CPU 52 through I/O 
pre-programmed manner to change the concentration of the circuit 56 to permit operating instructions to be input into the 
solution in crystallization chamber 14 to a desired value over memory 53 of CPU 52. Programming terminal 70 can 
a selected period of time. In preferred embodiments, sensors consist of any input device such as a keyboard, a touch 
are placed in the crystallization chamber, in the syringes, or 1~ screen, a bank of switches, push buttons, or the like. Once 
at appropriate positions to detect solution concentration, the operating instructions are stored in memory 53, pro- 
temperature, position, pressure or other variables, and one or gramming terminal 70 can be disconnected from I/O circuit 
more monitoring systems are used to monitor crystal nucle- 56 or can remain connected to I/O circuit 56. Display 80 also 
ation and growth in the crystallization chamber. The mea- is coupled to CPU 52 through I/O circuit 56 and serves to 
surements made by such sensors and monitoring systems 2o display operating parameters or status relating to the opera- 
during the crystallization process are used to control the tion of controller 40. For example, display 80 can be a CRT, 
crystallization process in a dynamic manner. Motor 20 can LCD display, LED display or similar device. Of course, 
then be stopped when it is determined that the concentration display 80 is optional. 
of the precipitant in crystallization chamber 14 has reached Once the operating instructions are stored in memory 53 
an optimum level for initiating crystallization (0.15 M salt, 25 through conventional programming and storage techniques, 
for example). Further, motor 20 can be operated to move the proper input voltage is supplied to input connector 60 
yoke 22 in a reverse direction, i.e. a direction opposite arrow and output connector 90 is coupled to stepper motor 20. 
x, to cause solution to flow from syringe 18 into crystalli- Controller 40 can control motor 20 to operate in a prede- 
zation chamber 14 and from crystallization chamber 14 into termined manner with respect to time to thereby control the 
syringe 16, to thereby raise the concentration of precipitant 30 crystallization process in a desired manner. Of course, if the 
in crystallization chamber 14. In this manner, the concen- initial concentrations of precipitant in reagent solutions in 
tration of precipitant in crystallization chamber 14 can be syringes 16 and 18 and in crystallization chamber 14 are 
finely adjusted and raised or lowered to a value which will known, and the volumes of crystallization chamber 14, 
stop, or even reverse, the crystallization process, thereby syringe 16, and syringe 18 are also known, the operating 
giving precise dynamic control of the crystallization pro- 35 instructions stored in memory 53 can be configured to 
cess. control the crystallization process, i.e., the concentration of 
Any appropriate motor can be used. For example, motor precipitant in crystallization chamber 14 in a dynamic 
20 can be a stepper motor (e.g., Model No. STP 42 ND manner with respect to time to provide desirable crystalli- 
4BLVE-100 manufactured by EPSON AMERICAN). zation conditions at all times. Input connector 100 includes 
Likewise, any type of controller, such as a digital or analog 40 inputs 11-14 for coupling additional inputs, such as limit 
programmable controller, that facilitates predetermined pro- switches, sensors, and the like, to CPU 52 through I/O 
grammable control of the crystallization process, as circuit 56. This permits closed-loop control to be achieved, 
described below, can be used to control motor 20 (e.g, the based on the state of the crystallization process or other 
MTSD-V1 motor driver, manufactured by MODERN variables. Additionally, these inputs can be coupled to 
TECHNOLOGY, INC.). For use in space, all components, 45 switches, or the like, for initiating, terminating, interrupting 
including the motor and controller may have to be certified or changing the operation of CPU 52. Of course the oper- 
or approved by the appropriate regulatory authority. ating instructions stored in memory 53 can be programmed 
FIG. 2 is a schematic illustration of controller 40 for in accordance with any desired operation and external inputs 
controlling motor 20 and thus the crystallization process. or outputs. 
Controller 40 is constituted of control circuit 50, input SO As noted above, one or more sensors can be attached to 
connector 60, programming terminal 70, display 80, output the crystallization chamber to provide feedback to permit 
connector 90, and input connector 100. Control circuit 50 closed loop control. For example, when the precipitant is a 
includes CPU (central processing unit) 52, I/O circuit 56, salt, a sensor which measures the electrical resistance or 
clock 54, and memory 53. Control circuit 50 can be a other electrical properties of a salt solution in crystallization 
conventional microprocessor-based device, such as a per- ss chamber 14 can be used to indicate the concentration of the 
sonal computer or an industrial programmable controller, or solution in the crystallization chamber, because electrical 
control circuit 50 can be a dedicated solid state, hard-wired, properties of the salt solution change as the concentration 
digital, analog or mechanical controller, for example. Clock changes. Additional sensors which measure pH and tem- 
54 generates pulses at regular intervals in a conventional perature of the reagent solution in the crystallization solution 
manner to provide timing for the operation of the other 60 can also be attached to crystallization chamber 14. Sensors 
components. Memory 53 contains operating instructions for that measure ionic strength and pH that are suitable for use 
CPU 52 to carry out the crystallization process. The oper- in the present invention can be obtained, for example, from 
ating instructions can be in the form of preprogrammed Microelectronics, Inc., 40 Harvey Rd., Bedford, N.H. Tem- 
software in the case of a digital controller, hard-wired perature sensors that are suitable for use in the present 
components in the case of an analog controller or mechani- 65 invention can be obtained, for example, from Bioserve 
cal elements, such as cams, in the case of a mechanical Space Technologies, University of Colorado, Boulder, Colo. 
controller. I/O circuit 56 provides an interface between CPU FIG. 4 is a top view of a preferred embodiment of a 
US 6,596,081 B1 
13 14 
crystallization chamber of the present invention, showing to a test tube, beaker, or other suitable container, into which 
the configuration for the attachment of a pH reference probe is placed a dialysis bag filled with a solution containing the 
62, a conductivity probe 63, a pH measurement probe 64, molecule to be crystallized. The test tube, beaker, or other 
and a temperature probe 65. The inlet tube 66, outlet tube 67, suitable container can then function as the above-described 
and screws 68 securing the top of the crystallization cham- 5 crystallization chamber, with the selected reagent solutions 
ber are also shown. FIG. 1 schematically illustrates an being pumped or injected into and out of the solution 
embodiment of the apparatus of the present invention com- holding the dialysis bag, to dynamically alter the composi- 
attached an ionic strength sensor 33, a pH, sensor 34, and a which Produces crystals. 
temperature sensor 35. Leads 36, 37, and 38 connect the As noted above, the apparatus of the present invention can 
sensors to ionic strength, pH, and temperature probes that include multiple, independently controlled sets of syringes 
are in contact with the reagent solution in crystallization that are attached to a crystallization chamber. In one such 
chamber 14. Output lines 56,57, and 58 carry ionic strength, embodiment, a first set of syringes can be attached to a 
pH, and temperature information to the controller (40 in crystallization chamber to deliver a solution containing a 
FIG. 2), and correspond to one or more of the inputs 11-14 1s precipitant that is appropriate for promoting nucleation and 
shown in FIG. 2. crystal growth, and a second set of syringes can be attached 
preferred embodiments of the present invention, crystal to the same crystallization chamber to deliver a solution 
nucleation and growth in the crystallization chamber are containing a salt that is appropriate for stabilizing and 
monitored by any of the methods known to those in the art storing the crystal for a Prolonged Period of time. Once a 
of growing molecular crystals. For example, the crystalli- 20 crystal of suitable size has been Produced by altering Pre- 
zation chamber can have a transparent cover, and crystal cipitant concentration using the first set of syringes, fluid 
nucleation and growth can be monitored by looking at the from the second set of syringes can be admitted into the 
contents of the reagent reservoir or dialysis sac within the reagent reservoir in the crystallization chamber through a 
crystallization chamber with an appropriate magnifying very narrow bore access tube (c0.2 mm) Or other suitable 
device; e.g., a microscope. Viewing and visual recording 2s outlet, while an equal volume of fluid from this area may be 
devices to image the interior of the crystallization chamber concurrently Pumped out ofthis area ofthe chamber through 
14 are not shown; however, such devices are commonly used a very narrow bore access tube (<0.2 mm) Or other suitable 
to evaluate crystal nucleation and growth, and can readily be outlet, until the desired concentration of stabilizing salt 
employed with the present invention by one in the solution in the crystallization chamber is attained. 
art. Such devices may include, but are not limited to, a 30 The foregoing disclosure describes embodiments of the 
camera to take static photographs, a video-recording device, present invention having a single crystallization chamber, as 
a magnifying device, and a magnifying device in tandem shown in FIG. 1. When conditions that produce crystals of 
with a video-recording device. Alternatively, early crystal useful size and quality are known, an apparatus having a 
growth can be detected by directing fiber optic leads to the single crystallization chamber can be used to efficiently 
reagent solution that direct light into the solution and 35 change the concentration of one or more precipitants, e.g., 
Feher, 1996, p. 184). As the crystallizing protein comes out nated manner to produce the conditions giving 
of the reactant solution, it changes the electrolytic properties crystallization, thereby permitting the time required for 
of the reagent solution. As a result, nucleating crystals can growing crystals to be shortened or optimized. The appara- 
solution that function as the plates of a capacitor. Frequency comparing crystal growth under diverse conditions; for 
changes of the RLC oscillator produced in this manner are example, in different gravitational fields, or at different 
an indication of crystal growth. temperatures. 
reagent solutions, and plungers of the syringes are moved by 4s tals for a given protein or other molecule are often unknown 
crystallization chamber(s). In embodiments having two or apparatus of the present invention that comprise multiple 
prising a single crystallization chamber 14 to which is tion of the solution surrounding the dialysis bag to one 
measure the light scattering (for example, see Durbin & salts, in the crystallization chamber in a controlled, coordi- 
be detected by introducing conductive wires into the reagent 40 tus having a single crystallization chamber is also useful for 
In the preferred embodiment, syringes are used to store The crystallization conditions giving well-ordered crys- 
a yoke to transfer the reagent solutions into and out of the or have not been optimized. In this case, embodiments of the 
more pairs of Source and drain syringes, each pair of crystallization chambers and are capable of varying multiple 
syringes can be coupled to a different motor-driven yoke so solution parameters in the different crystallization chambers 
that it can be operated independently of the others. However, so can be used to identify conditions that promote growth of 
any arrangement for delivering reagent solution to and from good crystals. 
the crystallization chamber(s) can be used. For example, two FIG. 5 schematically depicts a series of crystallization 
or more reservoirs, each pair having pumps which are chambers 91 that are connected to each other by small 
electrically or mechanically interlocked, can be used, or a diameter tubing 92, with the first and last crystallization 
single reservoir or syringe can be used and any excess ss chambers being connected via tubing to a source reservoir 
reagent solution can be allowed to drain into a reservoir or 93 and a drain reservoir 94 containing reagent solutions of 
the atmosphere, or a valve arrangement can be used. Any selected concentration. The source and drain reservoirs 
solution communicating means can be used as the solution referred to in FIG. 5 correspond to, and serve the same 
conduits that direct reagent solution between the reagent function as, respectively, syringes 16 and 18 in FIG. 1. In 
solution reservoirs and the crystallization chamber. For 60 one embodiment, all of the crystallization chambers in the 
example, plastic, glass, or metal tubing, or a fluid- series initially contain identical reactant and reagent solu- 
transporting channel in a chip (e.g., silicon), would be tions. As each drop of solution is injected from the source 
suitable for the present invention. Any mechanism can be syringe into the first cell in the series, an equivalent volume 
used to coordinate transfer of reagent solution to and from of solution is transferred from each cell into the tubing 
the crystallization chamber(s), such as a software interlock 65 leading “downstream” to the next adjacent cell in the series, 
programmed into the controller or any other mechanical and from the last cell to the drain syringe. Each drop of 
interlock. In addition, the reagent solution can be transferred reagent solution containing a high concentration of precipi- 
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tant that is injected from the source syringe mixes with the 
reagent solution in the first cell, and is diluted so that the 
reagent solution that is transferred from the first cell to the 
second cell has a lower concentration of precipitant than the 
drop which was injected into the first cell. The dilution of 
transferred reagent solution occurs in each subsequent cell in 
the series in like manner. Accordingly, the rate at which the 
concentration of precipitant increases is greatest in the 
In addition to controlling the concentration of one or more 
chemical precipitants to produce molecular crystals, the 
methods of the present invention permit and include con- 
trolling the physical parameters that can influence or pro- 
s mote crystal growth, or improve the quality of the crystals 
that are grown. For example, temperature is an important 
physical parameter affecting crystal growth, and the present 
invention includes use of a device to control temperature of 
crystallization chamber adjacent to the source reservoir, and the solutions in the crystallization chamber. Examples of a 
is successively lower in each successive chamber in the device for controlling the crystallization temperature include 
series. To have full control of the precipitant concentrations a Peltier cooler, a temperature controlled container, and 
in the cells, it is important that the reagent solutions do not heating coils imbedded in the system. 
flow or diffuse between cells except during controlled trans- As discussed above, another important physical parameter 
fers. TO prevent “crossflow,” very small diameter tubing is influencing crystal growth is gravity. Crystallization experi- 
used to connect the cells. Alternatively, valves can be 1s ments that have been conducted in space indicate that larger 
inserted in the lines of tubing 92 between the cells which are and more homogenous crystals can be grown in micrograv- 
only opened during the times when liquid is being trans- ity (111000 g to 1/10,000 g) environments by eliminating the 
ferred between cells. effects of the earth’s gravitational field. Example 2 below 
FIG. 6 schematically depicts an embodiment of the inven- describes the successful operation of the present invention in 
tion in which reagent solution is transferred from a source 2o producing protein crystals in the microgravity environment 
reservoir 93 via a manifold 95 to multiple crystallization of space. The apparatus of the present invention can be spun 
cells 91, each of which can vary in its initial reactant and/or by a centrifuge in space to subject the reactant molecules in 
reagent solutions, and from the crystallization cells 91 via the crystallization chamber to gravitational forces that are 
manifold 96 to a drain reservoir 94. With this embodiment, greater than the microgravity present in space, but less that 
crystallization processes can be monitored in a set of crys- 2s normal earth gravity. Alternatively, a centrifuge can be used 
tallization chambers having different initial conditions as the in space or on earth to subject the reactant molecules in the 
concentration of one or more precipitants is varied simul- crystallization chamber to a gravitational force that is greater 
taneously in all of the cells in a coordinate manner. than normal earth gravity. 
The present invention also includes configuring crystal- The advantages obtained by growing crystals in reduced 
lization chambers in two- and three-dimensional matrices 30 gravity in space can also be obtained by growing crystals in 
according to the teachings described above, in order to reduced effective gravitational fields such as those resulting 
analyze crystallization under a large number of different, from diamagnetic effects induced in a very high magnetic 
dynamically controlled conditions. FIG. 7 schematically field. In a strong magnetic field, diamagnetism causes the 
depicts a 2-D matrix of crystallization chambers 91 through electrons of molecules in the field to experience a force of 
which two different solutions, each containing one or more 35 repulsion or attraction that is dependent on the strength of 
precipitants, are pumped in different directions to produce the magnet and the distance of the molecules from the center 
independently controlled concentration gradients of the pre- of the magnet. In a sufficiently strong magnetic field, there 
cipitants across the rows and columns of cells. Paired source is a position with respect to the center of the magnet at which 
and drain syringes are operated in tandem, and the different matter will experience zero effective gravitational force 
sourceidrain pairs 1011102 and 1031104, respectively, are 40 (gerO), and the matter will levitate (Beaugnon et al., Nature 
operated sequentially. Cross-flow between cells is prevented (1991) 349:470). When moved to different positions with 
by using small bore tubing to connect the cells, and if respect to the center of the magnet, the matter experiences 
necessary, valves in the lines between the cells which only effective gravitational forces that range between zero and 
open when fluid is being transferred. normal earth gravity. At other positions with respect to the 
In like manner, the effects on crystallization of varying the 4s magnet’s center, and depending on the strength of the 
concentration of one or more additional precipitants in magnetic field, the matter experiences effective gravitational 
forces ranging from one to twenty times the gravity at 
netting the crystallization chambers of two or more earth’s surface. The same real-time, remote-controlled 
matrices, e.g., in a ‘‘stack,” to form a third dimension across operative capabilities, compactness, and ease of use that 
which one or more gradients of precipitant concentration is so permit the apparatus and method of the present invention to 
established. The paired source and drain syringes controlling be used in microgravity environments of space also Permit 
flow of the additional reagent solutions into crystallization the present invention to be used efficiently in the restricted 
chambers of the first matrix, and out of chambers of the last environments in which very high magnetic fields are pro- 
matrix, are operated in tandem, and are operated sequen- duced to grow crystals in effective gravitational fields rang- 
tially with respect to the other pairs of syringes, in the ss ing from zero to about twenty times the gravity at earth’s 
manner described above for paired syringes in the 2-D surface. An added benefit obtained by growing crystals in a 
matrix. Of course, there are innumerable variations and magnetic field capable of generating strong diamagnetic 
combinations of the configurations of the invention forces is that the molecules in such a field tend to be aligned 
described above which can also be employed to analyze in the same direction, which promotes the growth of ordered 
crystallization, e.g., by using multiple, independently con- 60 crystals. 
trolled source syringes connected to the same or different To grow crystals under a range of different effective 
cells in a given dimension, and by varying the initial gravitational forces, a vertical assembly of crystallization 
conditions in the crystallization chambers. Such variations chambers 71 supported by support strip 72 is placed in the 
of the method and apparatus described herein are easily bore 73 of a high field magnet (e.g., 16 T), as shown in FIG. 
within the ability of those skilled in the art of producing 65 8. Each crystallization chamber 71 consists of a reactant 
molecular crystals, and are also included in the present reservoir of about 1 ml volume which communicates with 
invention. the reagent chamber (a few mm3 volume) through a dialysis 
multiple crystallization chambers can be observed by con- 
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membrane, as described previously. Hence, each crystalli- 
zation chamber is at a different gefvalue, and also a different 
magnetic field value. For a given magnetic field value, the 
crystallization chamber can be positioned for the g,rO 
condition by adjusting the entire stack. It is important to note 
that the stack does not levitate. Rather, it is the reactant 
crystallites in the specific cell where g,rO which will 
experience no net force over a distance of less than 1 mm. 
Each chamber in the stack samples a gradual variation of g, 
with position as shown in FIG. 8. Those chambers above 
magnet center are at g,6g, whereas those below are at 
g,+g. The chamber in the center represents the control 
experiment where the magnetic field is present, but g , r g .  
The first crystallization chamber 71 shown in FIG. 8 is 
connected to a reagent solution source reservoir by inlet tube 
74. Small-diameter tubing connects each of the crystalliza- 
tion chambers to the next one in the series, and the last 
chamber in the series is connected to a drain reservoirs by 
return tube 75. This configuration of crystallization cham- 
bers is similar to that shown in FIG. 5 .  By controlling the 
flow of reagent solution containing one or more precipitants 
through the series, a concentration gradient of precipitant 
can be established across the series of crystallization cham- 
bers. By this means, it is possible to grow crystals in a 
multifactorial environment in which both precipitant con- 
centration and effective gravitational field are varied. 
Moreover, the total magnetic field is also variable; it can be 
varied anywhere from about 16 to 33 Tesla. This shifts the 
g , r ( 2  to 6) g and the g,rO points farther away from the 
center of the magnet. For fields less than 16 T, the g,rO 
condition cannot be maintained, but a finer variation for the 
condition 2 g <g,fig can be obtained. 
In one embodiment of the invention, the magnet is a 
water-cooled resistive magnet, and the controller can adjust 
the temperature of the magnetic bore to temperatures 
between 10 and 40" C. once it reaches a steady state, to give 
control over an additional physical parameter affecting crys- 
tal growth. In a different embodiment, the magnet is a 
superconducting magnet that is kept cold in a cryogenic 
container, similar to the magnets used by nuclear magnetic 
resonance (NMR) spectroscopists or clinical magnetic reso- 
nance imaging (MRI) specialists, for which access to the 
magnetic field region of interest is at a temperature selected 
by the controller; e.g., room temperature. 
EXAMPLES 
Crys ta l s  of carboxy pept idase-A (CPA) and 
concanavalin-A (CON-A) were produced under normal 
earth gravitational conditions (1 g) using the methods and 
apparatus of the present invention. Using the present 
invention, crystals of Ribonuclease S were grown both on 
earth at 1 g, and in the microgravity environment on board 
the Space Shuttle (Flight STS-95). The crystallization cham- 
ber in the apparatus used for the experiments has a volume 
of 1 ml. 
Example 1 
Crystallization of CPA 
In the experiments with CPA, the protein was disposed in 
a dialysis bag in 50 microliters of solution of 1.2M LiCl at 
a pH of 7.5 at a protein concentration of 12 mgiml. The 
dialysis bag was then placed in the crystallization chamber 
and the remainder of the crystallization chamber was filled 
with a 1.2M solution of LiCl at pH of 7.5. One of the 
syringes was loaded with a 0.1M solution of LiCl at pH of 
5 
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20 
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so 
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7.5 which was injected into the crystallization chamber. 
Several trials were conducted under these initial conditions 
with the amount of salt solution transferred from the syringe 
to the crystallization chamber being different in each trial. In 
each trial, the amount of salt solution transferred from the 
crystallization chamber was equal to the amount of salt 
solution transferred to the crystallization chamber, as 
described above. Each of the mixing times was under 1 
minute. 
The results of the crystallization tests for CPA are pre- 
sented below in Table 1. 
TABLE 1 
Trial initial ml. of .1M 
# CC solution LiCLl7.5 injected Results 
1 1.2M LiC117.5 3 ml. No crystals 
2 1.2M LiC117.5 4 ml. No crystals 
3 1.2M LiC117.5 5 ml. Large crystals 
4 1.2M LiC117.5 6 ml. Large crystals 
5 1.2M LiC117.5 6.5 ml. Large crystals 
It can be seen that trials 1 and 2 did not lower the 
concentration of the salt solution in the crystallization cham- 
ber enough to produce large crystals. However, in trials 3-5 
larger amounts of low concentration salt solution were 
transferred into the crystallization chamber and thus the 
concentration of salt solution was lowered into a range in 
which the protein can come out of solution to form large 
crystals. The results of trials 3-5 compared favorably to a 
control trial using a conventional dialysis method of crys- 
tallization. In the control trial a 50 pl dialysis bag was filled 
with CPA at a concentration of 12 mgiml in 1.2M LiCl at a 
pH of 7.5. The dialysis bag was then suspended in 1 ml of 
0.1M LiCl at a pH of 7.5. While the control trial yielded 
large crystals it could not be dynamically or remotely 
controlled because once the dialysis bag was placed in the 
salt solution, crystallization conditions could not be altered. 
Example 2 
Crystallization of Ribonuclease in Space 
Ribonuclease S protein was purchased from Sigma 
chemical company. The protein was dissolved to a concen- 
tration of 24 mgiml in a solution of 25% ammonium sulfate, 
25% sodium chloride, 0.1 M Na-acetate, pH 5.0, and was 
dialyzed against the same solution overnight. At this 
concentration, protein crystallization begins at about 75% 
total salt saturation of the precipitant solution. This level was 
reached at a gradual rate through dialysis in the Dynamically 
Controlled Crystallization System (DCCS) of the present 
invention, and through vapor diffusion in hanging drops. All 
solutions included a standard 25% saturated ammonium 
sulfate and 0.1 M Na-acetate, pH 5.0. In all cases, the only 
precipitant that was varied was sodium chloride. Crystalli- 
zation generally occurs when the concentration of NaCl 
reaches 47-52% saturation. The preliminary hanging drop 
trials were carried out in linbro plates from Hampton 
research. The reservoirs were filled with solution containing 
precipitant at concentrations expected to give precipitation. 
They were made by mixing 250 microliters of saturated 
ammonium sulfate, 40 microliters 2.5 M Na-acetate, 
470-600 microliters of saturated NaC1, and water to 1 ml 
volume. The amounts of NaCl were selected to scan a broad 
range, to find the value that gave the best crystals. The 
hanging drops were formed by mixing equal 5-microliter 
volumes of protein solution and reservoir solution on a 
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siliconized coverslide, also from Hampton Research. The scope. The crystals were first photographed with a Nikon FX 
drops were kept at room temperature (24” C.). The process camera through the dialysis membrane, while remaining in 
of vapor diffusion in a sealed system gradually increased the their growth environment. This allows comparison of where 
and nucleation occurred. Other trials were Performed using s moved in the event damage occurs during that process. Next, 
the DCCS of the present invention. In the method used in the procedure involved removing them from the original 
this example, the Source syringe was filled with the PreciPi- protein chamber and placing them in artificial mother liquor 
tant solution at the expected level of crystallization. The in hanging drops, The mother liquor solution consisted of 
reservoir was filled with a lower level of a similar solution. 60% sodium chloride, 24% ammonium sulfate and 1 M 
It would include the standard ingredients and only 35-4092 i o  sodium acetate. Crystals that were free floating in the growth 
sodium chloride. This concentration is too low to nucleate chamber were simply inverted onto a coverslide and poured 
Ribonuclease s crystals. These units were also kept at room out of the chamber. However, those that had grown stuck to 
temperature throughout the trials. As the motor Pushed the the various walls of the chamber and to the membrane had 
Source syringe Plunger, the syringe was emptied into the to be gently detached from the surface with a fiberloop and 
reagent reservoir of the CrYstalliZation chamber and gradu- 15 physically placed into hanging drops. At his point the crystal 
ally increased the precipitant concentration in that reservoir sizes were measured using a microscope, Morpho~ogy and 
to that of the source syringe solution. The precipitant in the defect observations were also made and documented, pho- 
reagent solution in the crystallization chamber then diffused tographs were then taken again while in this hanging drop 
across the dialysis membrane into the reactant chamber until environment with the Same camera and later transferred into 
the precipitant concentration therein reached the precipitant 2o digital image files, once well documented on film and 
concentration of the reagent solution, and nucleation stabilized in solution, the crystals were mounted in 1.0 mm, 
occurred. siliconized glass capillaries for X-ray diffraction analysis. 
reproducible, as expected. At a sodium chloride concentra- Upon landing of the STS-95, ribonuclease crystals were 
tion of about 53% saturation a few small crystals would 25 Seen in all DCCS units except the two spares which did not 
appear overnight. They tended to be about 0.1 mm in size produce any crystals. Observations made while crystals 
and usually did not have a standard crystal shape. The edges remained in the protein chambers showed little difference in 
were not straight, probably because the growth was too fast. the two growth environments. Approximately the same 
When nucleation occurs too rapidly, the result is too many number of crystals were present in each of the corresponding 
crystals of insufficient size with sub-standard morphology. A 30 ground and space units, as expected. The amount of crystals 
better precipitant concentration is around 47-50% sodium recovered in both environments followed the expected 
chloride. At these levels, nucleation yields about 1-5 curve. (See Table 2.) The higher the precipitant concentra- 
crystals, some of which grow to over 1 mm, which is ideal. tion the more nucleation and the smaller the crystals. Crys- 
The DCCS units yield a few more crystals because the tals grown in space were approximately equal in size to their 
volume of the protein chamber is much greater than that of 35 ground-grown counterparts. The crystal yields (fraction of 
a hanging drop. The 50 ul chambers in the units contain 1.2 protein that was actually incorporated into crystals) were 
mg of protein whereas the 10 ul hanging drops only contain roughly similar. The major difference in the two was found 
0.12 mg of RNase S protein. Space experiment setups: when harvest time came. As usual, a common problem arose 
For the final DCCS preparation for the STS-95 mission of in the ground units; the crystals grown on the ground 
space shuttle Discovery, the loading was similar to that in 40 adhered to the walls and membrane of the chamber and were 
laboratory trials. Four DCCS units were loaded for the difficult to remove without damage. Throughout all four 
SpaceHab payload bay module and six were loaded to ground units about 80% of the crystals were stuck and, in 
remain on the ground in the SpaceHab facility, Cape particular, the biggest and best were the most difficult to 
Canaveral, Fla. Four of the six ground units were the harvest. The crystals that were grown in microgravity were 
positive controls and were placed into a 24” C. Incubator. 45 about 80% loose and free-floating in their growth solution. 
The other two units were brought as spare units and were These crystals “poured” out onto coverslides with little or no 
placed outside of the incubator on the lab bench. They were handling necessary. 
also kept at approximately 24” C. The conditions in the 
source syringes for the flight units were 47% sodium chlo- 
ride in unit FOO, 50% in F01, 53% in F02, 53% in F03 and SO 
the starting reservoirs were filled with 35% sodium chloride. 
The six ground units were loaded as follows: 47% sodium 
in the incubator, and 50% in GO3 and 53% in the two outside Unit Growth Concentration Crystals mm mm Yield 
salt concentration in the drop to the level in the reservoir, in the chamber they grew and their appearance before being 
Both methods produced similar crystals and were Results 
TABLE 2 
Overview of DCCS Individual Unit Results. 
Location Avg. Largest 
chloride in GOO, 47% in G04,50% in G01, and 53% in GO2 of %NaCl Number of Size Size % 
47 3 1.2 1.6 8 
The mission length of STS-95 was 10 days. The computer F01 Soace so 6 1.15 1.3 14 
the incubator. The reservoirs were initially filled with 35%. ss FOO Space 
program ran and syringes moved for the first 3.5 days of the FOZ Space 53 35 0.6 0.7 11 
47 1 1.5 1.5 5 
so 4 1.2 1.4 10 
and the remainder of the time the crystals could continue to 60 ~ 0 2  Incubator 53 40 0.55 0.6 10 
mission. Accordingly, the solution containing the protein F03 53 30 0.55 0.7 7 
would take 3.5 days to reach the expected nucleation point, 
grow. GO3 Bench 53 0 0  0 0 
ing 
After the mission, the DCCS units were then shipped from 
Florida to the Center for Advanced Research in Biotechnol- 65 
ogy (CARB) in Gaithersburg, Md., and opened there. The 
crystals were counted through the membrane using a micro- 
~~~~~’~~~ 
Harvesting, Photography, Analysis of Crystals and Mount- Go4 Incubator 47 1 1.4 1.4 4 
GO5 Bench so 0 0  0 0 
Although the crystals from earth and space were generally 
similar in appearance there were some differences. Crystals 
from both environments typically had six well-developed 
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faces, with the two tips slightly rounded. Because the ground 
crystals were more often stuck to the wall, they tended to 
have less complete, perfect shapes. Conversely, because the 
space crystals were unattached and free to tumble around, 
they had more uniform overall shape. However, due to the 
tumbling the space crystals occasionally had minor damage 
to edges and tips, but not enough to significantly interfere 
with their analysis. 
The computer program ran to completion, as expected. All 
source syringes came back empty and the drain syringes 
were full. 
Discussion 
The mission was a success having all the initial goals met. 
Large crystals were obtained from both space and ground 
experiments. Topography analysis requires crystals that are 
at least 0.5 mm, and several crystals of this size from both 
environments and various precipitant conditions were recov- 
ered. The size and number of RNase S crystals followed 
what was seen in the preliminary experiments with the size 
and number increasing with increasing salt concentration 
and decreasing in size (See Table 2.). 
The primary difference observed was that crystals adhered 
to the walls of the protein chamber in the ground units, while 
the majority of the crystals grown in microgravity were 
loose crystals. The size and quality of the crystals does not 
matter if they cannot be harvested from their growth envi- 
ronment. The earth-grown crystals grew about as well as the 
space grown, and this is captured on film. However, damage 
done during harvesting caused them to be lesser in quality 
for purposes of analysis. Cracks often occurred and frag- 
mented corners were a common problem when breaking 
them free of the surfaces on which they grew. 
All publications, patents, and patent applications men- 
tioned in the above specification are incorporated herein by 
reference. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure 
by virtue of prior invention. Various modifications and 
variations of the described methods and system of the 
invention will be apparent to those skilled in the art without 
departing from the scope and spirit of the invention. 
Although the invention has been described in connection 
with specific embodiments, it should be understood that the 
invention as claimed is not limited to such specific 
embodiments, and that various modifications of the 
described modes for carrying out the invention which are 
obvious to those skilled in the arts to which this invention 
pertains are intended to be within the scope of the following 
claims. 
We claim: 
1. An apparatus for crystallizing molecules comprising: 
at least one crystallization chamber configured to contain 
a reactant solution comprising a molecule to be crys- 
tallized and a reagent solution comprising at least one 
precipitant, which solutions are in contact with, and 
separated by, one of a permeable membrane and a 
permanent sieve comprising pores that are large enough 
to permit passage of said at least one precipitant, but 
not large enough to permit passage of the molecules to 
be crystallized, from one solution to the other; 
at least one first reagent solution reservoir and at least one 
second reagent solution reservoir, said first and second 
reagent solution reservoirs being configured to contain 
respective reagent solutions comprising said at least 
one precipitant; 
at least one first communicating means for communicat- 
ing said first reagent solution reservoir with the reagent 
solution in said crystallization chamber; 
22 
at least one second communicating means for communi- 
cating said second reagent solution reservoir with the 
reagent solution in said crystallization chamber; 
at least one first transfer means for selectively transferring 
solution between said first reagent solution reservoir 
and the reagent solution in said crystallization chamber; 
at least one second transfer means for selectively trans- 
ferring solution between said second reagent solution 
reservoir and the reagent solution in said crystallization 
interlocking means for interlocking said first transfer 
means and said second transfer means to cause said first 
transfer means and said second transfer means to 
reversibly transfer equal volumes of reagent solution 
into and out of said crystallization chamber. 
2. An apparatus as recited in claim 1, further comprising 
dynamic control means coupled to said first transfer means 
and said second transfer means for controlling the amounts 
2o of reagent solutions transferred by said first transfer means 
and said second transfer means. 
3. An apparatus as recited in claim 1, wherein said first 
reagent solution reservoir and said first transfer means 
comprise a first syringe, and said second reagent solution 
25 reservoir and said second transfer means comprise a second 
syringe. 
4. An apparatus as recited in claim 3, further comprising 
a motor operatively coupled to said first syringe and said 
second syringe, said motor being a part of said first transfer 
5 .  An apparatus as recited in claim 4, wherein said 
interlocking means comprises a yoke operatively coupled 
between said motor and said first syringe and said second 
syringe, 
wherein said first transfer means and said second transfer 
means act in opposition to one another so that when 
said first transfer means transfers a volume of solution 
from said first reagent solution reservoir to said reagent 
solution in said crystallization chamber, said second 
transfer means transfers an equal volume of solution 
from said reagent solution in said crystallization cham- 
ber to said second reagent solution reservoir, 
5 
lo chamber; and 
15 
3o means and said second transfer means. 
35 
40 
and vice versa. 
6. An apparatus as recited in claim 5,  further comprising 
45 a guide rod, said yoke being mounted on said guide rod, and 
further being disposed to slide on said guide rod. 
7. An apparatus as recited in claim 6, wherein said first 
and second transfer means further comprise a lead screw 
coupled to a shaft of said motor, said lead screw being 
8. An apparatus as recited in claim 4, wherein said control 
means is operatively coupled to said motor to control 
transfer of the reagent solution. 
9. An apparatus as recited in claim 1, wherein said 
ss crystallization chamber comprises a container in which a 
dialysis membrane is interposed between the reagent solu- 
tion and the reactant solution. 
10. An apparatus as recited in claim 1, further comprising 
means for measuring parameters of the reagent solution in 
60 said crystallization chamber selected from at least one of 
conductivity, pH, and temperature. 
11. An apparatus as recited in claim 1, further comprising 
means for monitoring at least one of crystal nucleation and 
growth in the reactant solution in said crystallization cham- 
12. An apparatus as recited in claim 1, further comprising 
means for dynamically controlling, in real time, parameters 
SO engaged with said yoke via a threaded bushing. 
65 ber. 
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of the reagent solution in said crystallization chamber 
selected from at least one of conductivity, pH, and 
temperature, and effective gravity. 
means for selectively starting and stopping a crystallization s 
process in said crystallization chamber. 
14. An apparatus as recited in claim 1, comprising two or 
more crystallization chambers connected in series via solu- 
tion communicating means; wherein said first reagent solu- 
tion reservoir is connected via solution communicating 
means to the crystallization chamber at one end of the series, 
and said second reagent solution reservoir is connected via 
solution communicating means to the crystallization cham- 
ber at the other end of the series. 
more crystallization chambers, each of which is connected 
via solution communicating means to said at least one first 
reagent solution reservoir. 
16. An apparatus as recited in claim 1, further comprising 
at least one additional pair of reagent solution reservoirs that 20 
are respectively connected by solution communicating 
means to the reagent solution in said at least one crystalli- 
zation chamber, 
wherein the initial concentration of said at least one 
precipitant in the reagent solutions in said at least one 2s 
additional pair of reagent solution reservoirs is not the 
same as the initial concentration of said at least one 
precipitant in said first and second reagent solution 
reservoirs; 
and interlocking means for selectively transferring 
reagent solutions between said at least one additional 
pair of reagent solution reservoirs and said reagent 
solution in said at least one crystallization chamber, 
wherein said solution transfer means for operating each of 
said pairs of reagent solution reservoirs, including said 
first and second reagent solution reservoirs, operate 
sequentially with respect to each other. 
17. An apparatus for crystallizing molecules comprising: 4o 
at least one crystallization chamber configured to contain 
a reactant solution comprising a molecule to be crys- 
tallized and a reagent solution comprising at least one 
precipitant, which solutions are in contact with, and 
separated by, one of a permeable membrane and a 
to permit passage of said at least one precipitant, but 
not large enough to permit passage of the molecules to 
be crystallized, from one solution to the other; 
reagent solution reservoir, said first and second reagent 
solution reservoirs being configured to contain respec- 
tive reagent solutions comprising said at least one 
precipitant; 
at least one first conduit coupling said first reagent solu- 
tion reservoir with said reagent solution in said crys- 
tallization chamber; 
at least one second conduit coupling said second reagent 
solution reservoir with said reagent solution in said 
CrYstalliZation chamber; 
at least one first transfer mechanism configured to selec- 
tively transfer solution between said first reagent solu- 
tion reservoir and said reagent solution in said crystal- 
lization chamber; 
at least one second transfer mechanism configured to 
selectively transfer solution between said second 
reagent solution reservoir and said reagent solution in 
said crystallization chamber; and 
an interlock coupling said first transfer mechanism and 
said second transfer mechanism to said first 
transfer mechanism and said second transfer mecha- 
nism to reversibly transfer equal volumes of reagent 
solution into and out of said crystallization chamber. 
18. The apparatus according to claim 1, further compris- 
a support strip, said at least one crystallization chamber 
comprising a plurality of crystallization chambers 
mounted in a vertical assembly on said support strip; 
a magnet having a bore defined through a center of the 
magnet, said support strip being adjustably positioned 
in the bore, whereby a net force acting on the crystal- 
lization chambers simulates crystallization in a micro- 
gravity environment, 
19. The apparatus according to claim 18, wherein said 
20. The apparatus according to claim 18, wherein said 
13. An apparatus as recited in 1, further comprising at least one first reagent solution reservoir and one second 
15. An apparatus as recited in claim 1, comprising two or IS 
and further comprising additional solution transfer means 30 ing: 
3s and 
magnet is a water-cooled resistive magnet. 
magnet is a superconductor magnet. 
permanent sieve comprising pores that are large enough * * * * *  
